

Sent: Tuesday, March 27, 2007 11:18 AM
To: Alana Miller

Subject: Ezetimibe for the treatment of primary hypercholesterolaemia

Importance: High

Dear Alana

Re: Ezetimibe for the treatment of primary (heterozygous familial and non familial) hypercholesterolaemia – Appraisal Consultation Document

Thank you very much for your assistance in facilitating Action Heart's involvement in the above appraisal.

This communication is to inform you that Action Heart has no major queries or concerns with the Appraisal Consultation Document (ACD). However, Action Heart would like to make the following observations for the Appraisal Committee to consider.

a.. Item 2.4 (page 5) As Action Heart is committed to educating patients with respect to the benefits to be gained via lifestyle changes, it would welcome the addition of physical activity and weight management to the list of 'other factors'.

a.. On a more general note if the Final Appraisal Document (FAD) is to assist patients via their improved knowledge and involvement in their condition it may be helpful to include advice on, for example, how soon after a change in medication (drug/dose) the lipid profile should be reassessed to determine the success of the new prescription.

a.. On a similar note (Item 1.2, page 1-2) it may be helpful to alert patients that more 'trivial' side effects may be experienced and include guidance on how quickly these should be discussed with their consultant/GP.

Once again, many thanks for your assistance with this appraisal and Action Heart look forward to receiving the outcome of the Second Appraisals Committee Meeting.

Yours sincerely

On behalf of the Action Heart Patient Advocacy Group

PS Please be advised that Action Heart has no comments with respect to the Evaluation Report for this appraisal.

Delivered via MessageLabs

This email and any files transmitted with it are confidential and intended solely for the use of the individual or entity to whom they are addressed. If you have received this email in error please notify the sender by telephone on 01384 292233 and return it to the sender at the above address. This message contains confidential information and is intended only for the individual named. If you are not the named addressee you should not disseminate, distribute or copy this email.